Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 67 clinical trials
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

was FDA approved in 2017 for the treatment of certain types of bladder cancer, but has not been approved for use in Head and Neck cancer patients. Durvalumab is an experimental drug that uses

squamous cell carcinoma of the head and neck
immunomodulator
durvalumab
carcinoma of the head and neck
primary tumor
  • 19 views
  • 24 Jan, 2021
  • 2 locations
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

specific changes in cancer cell DNA to treat patients with advanced cancer. The primary endpoint is anti-tumor activity or stable disease documented after 16 weeks of experimental drug treatment. The drugs

primary cancer
erlotinib
primary tumor
measurable disease
trastuzumab
  • 0 views
  • 25 Jan, 2021
  • 7 locations
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)

experimental drug used in this study is called ibrutinib and the second is called pembrolizumab. This is the first time that ibrutinib will be used in combination with pembrolizumab. This combination

chronic lymphocytic leukemia
ibrutinib
tumor cells
cancer
lymphocytic leukemia
  • 88 views
  • 15 Mar, 2021
  • 1 location
Trial to Evaluate CIS43LS in Healthy Adults

malaria, there is no vaccine that fully prevents infection. Researchers want to test if an experimental drug can help. Objective To test a drug called CIS43LS that

chmi
oophorectomy
blood donation
antimalarials
  • 10 views
  • 28 Apr, 2021
  • 1 location
Rigosertib for RDEB-SCC

efficacy and safety of systemic treatment regimens for advanced SCC, the investigators propose to perform a small, "first in EB " trial of an experimental drug called rigosertib for the treatment of EB

gemcitabine
cetuximab
measurable disease
nivolumab
panitumumab
  • 30 views
  • 02 Apr, 2021
  • 1 location
A Multi-center Non-randomized Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin Vindesine Dacarbazine) Under the Guidance of PET/CT

The experimental drug regimen in this study includes a PD-1 antibody (tislelizumab) single-drug induction treatment period and a PD-1 antibody + AVD combined treatment period. PD-1

  • 0 views
  • 18 Apr, 2021
  • 1 location
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

This study will examine the safety of giving the experimental drug, resiniferatoxin (RTX), to treat severe pain in patients with advanced cancer. RTX is a chemical extracted from a cactus-like

weakness
analgesics
anticoagulant
blood products
sensory testing
  • 326 views
  • 09 May, 2021
  • 1 location
Carboplatin Nab-Paclitaxel Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

for squamous lung cancer, but experimental for head and neck cancer. Durvalumab is an experimental drug that uses the body's own immune system to fight the cancer. Doctors hope that combining

immunomodulator
durvalumab
carcinoma of the head and neck
cavity
intensity-modulated radiation therapy
  • 101 views
  • 24 Jan, 2021
  • 2 locations
99m Tc-3PRGD2 SPECT/CT Imaging in the Diagnosis of Lymph Node Metastasis of Esophageal Carcinoma

The esophageal squamous cell carcinoma (ESCC) has high prevalence and mortality in China, which become a severe challenge for public health. The molecular imaging technology has been developed for visualization and precise diagnosis of the tumors. Integrin v3 is a specific marker for tumor. Noninvasive visualization and quantitative analysis of …

esophageal cancer
esophagus cancer
metastasis
ct scan
esophageal carcinoma
  • 0 views
  • 25 Jan, 2021
  • 1 location
QUILT-3.017: Study of NEO-201 in Solid Tumors

This is an open label, first-in-human, phase 1, dose escalation study to determine the safety including dose limiting toxicity (DLT) and maximal tolerated dose of the monoclonal antibody NEO-201 in adults with solid tumors (cancer) which has not responded to standard treatments.

lung cancer
antineoplastic
monoclonal antibody neo-201
pancreatic cancers
adenocarcinoma
  • 40 views
  • 23 Jan, 2021
  • 1 location